2025-01-12 - Analysis Report
## Johnson & Johnson (JNJ) Stock Report

**1. Performance vs. S&P 500 (VOO):**

Johnson & Johnson is a multinational healthcare company that manufactures medical devices, pharmaceuticals, and consumer packaged goods.  The provided data shows JNJ's cumulative return significantly lagged behind the S&P 500 (VOO).  While JNJ had a cumulative return of 21.25%, VOO achieved a return of 112.20%. This represents a substantial underperformance of -90.9% relative to the S&P 500, placing it at the 6.9th percentile of its historical performance range against the index.

**2. Recent Price Movement:**

* **Closing Price:** $142.06
* **5-day Moving Average:** $143.68
* **20-day Moving Average:** $144.74
* **60-day Moving Average:** $152.25

The stock price is currently below all three moving averages, indicating a short-term downtrend.

**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 41.19 – Suggests the stock is approaching oversold territory, but not decisively so.
* **PPO (Percentage Price Oscillator):** 0.08 – A slightly positive value, indicating a weak bullish momentum.
* **20-Day Relative Divergence:** -0.2 – Shows a recent short-term decline in relative performance against the market.
* **Expected Return (2+ years):** -371.4% – This extremely negative figure suggests a significant underperformance against the S&P 500 is expected over the long term.  This warrants further investigation and likely reflects a highly pessimistic outlook based on the data provided.  It's crucial to understand the methodology behind this dramatic prediction.


**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue       |
|------------|---------|---------------|
| 2024-10-23 | $1.12   | $22.47B       |
| 2024-07-25 | $1.95   | $22.45B       |
| 2024-05-01 | $1.35   | $21.38B       |
| 2024-02-16 | $1.68   | $21.39B       |
| 2023-10-27 | $10.32  | $21.35B       |

There's a significant outlier in October 2023 EPS ($10.32), which drastically skews the trend.  Without further information, it's difficult to determine whether this is an anomaly or a genuine data point.  Excluding this data point, EPS shows a generally downward trend. Revenue remains relatively stable, though without a significant upward trend.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2024-09-30 | $22.47B  | 69.01%        |
| 2024-06-30 | $22.45B  | 69.40%        |
| 2024-03-31 | $21.38B  | 69.55%        |
| 2023-12-31 | $21.39B  | 68.23%        |
| 2023-09-30 | $21.35B  | 69.06%        |

Revenue is relatively stable, with only minor fluctuations. Profit margins remain consistently high, indicating strong profitability.

**Capital and Profitability:**

| Quarter | Equity    | ROE          |
|---------|-----------|--------------|
| 2024-09-30 | $70.16B  | 3.84%        |
| 2024-06-30 | $71.54B  | 6.55%        |
| 2024-03-31 | $70.02B  | 4.65%        |
| 2023-12-31 | $68.77B  | 5.89%        |
| 2023-09-30 | $71.23B  | 36.54%       |

Equity shows some fluctuation.  ROE is highly volatile, with the outlier in Q3 2023 (36.54%) significantly impacting the trend.  Further investigation is needed to understand the factors driving this variation.

**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 over the period analyzed. While the company maintains strong profitability and relatively stable revenue,  recent earnings show a concerning downward EPS trend (excluding the October 2023 outlier). The projected long-term return against the S&P 500 is extremely negative (-371.4%), requiring careful examination of the calculation's methodology. Technical indicators suggest a potentially oversold market, but not a strong buy signal. The significant variation in ROE and the unexplained outlier in Q3 2023 EPS raise serious concerns requiring further investigation before making any investment decisions.  The data provided raises significant red flags about JNJ’s future performance relative to the broader market.

**8. Disclaimer:** This report is based solely on the provided data and is not financial advice.  Independent research and professional consultation are recommended before making any investment decisions. The highly negative projected return should be viewed with extreme skepticism until the underlying methodology is understood and validated.  The outlier data points require further investigation to ensure data accuracy.
